Anemia In Chronic Kidney Disease Market

DelveInsight's "Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Anemia In Chronic Kidney Disease, historical and forecasted epidemiology as well as the Anemia In Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Anemia In Chronic Kidney Disease market report provides current treatment practices, emerging drugs, Anemia In Chronic Kidney Disease market share of the individual therapies, current and forecasted Anemia In Chronic Kidney Disease market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current Anemia In Chronic Kidney Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Anemia In Chronic Kidney Disease market.

Anemia In Chronic Kidney Disease Treatment Market

The DelveInsight’s Anemia In Chronic Kidney Disease market report gives a thorough understanding of Anemia In Chronic Kidney Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Anemia is a common complication of chronic kidney disease (CKD). CKD means the kidneys are damaged and cannot filter blood the way they should. This damage can cause wastes and fluid to build up in body.

Anemia is common in people with CKD, especially among people with more advanced kidney disease. More than 37 million American adults may have CKD, and it is estimated that more than 1 out of every 7 people with kidney disease have anemia. Most people who have kidney failure, when kidney damage is so advanced that less than15 percent of the kidney is working normally, also have anemia.

People with CKD who also have diabetes are at greater risk for anemia, tend to develop anemia earlier, and oftenhave more severe anemia than people with CKD who don't have diabetes. People older than 60 are also more likely to have anemia with CKD.

Anemia related to CKD typically develops slowly and may cause few or no symptoms in early kidney disease.

Symptoms of anemia in CKD may include, fatigue or tiredness, shortness of breath, unusually pale skin,weakness, body aches, chest pain, dizziness, fainting, fast or irregular heartbeat, headaches, sleep problems, andtrouble concentrating. Anemia in people with CKD often has more than one cause. When kidneys are damaged, they produce lesserythropoietin (EPO), with less EPO, body makes fewer red blood cells, and less oxygen is delivered to yourorgans and tissues. In addition to your body making fewer red blood cells, the red blood cells of people withanemia and CKD tend to live in the bloodstream for a shorter time than normal, causing the blood cells to diefaster than they can be replaced.

Anemia In Chronic Kidney Disease Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Anemia In Chronic Kidney Disease.

Anemia In Chronic Kidney Disease Treatment

It covers the details of conventional and current medical therapies available in the Anemia In Chronic Kidney Disease market for the treatment of the condition. It also provides Anemia In Chronic Kidney Disease treatment algorithms and guidelines in the United States, Europe, and Japan.

Anemia In Chronic Kidney Disease Epidemiology 

The Anemia In Chronic Kidney Disease epidemiology section provides insights about the historical and current Anemia In Chronic Kidney Disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Anemia In Chronic Kidney Disease market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Anemia In Chronic Kidney Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

• According to the study conducted by Steven F. et al. (2018), in patients with stage 3 CKD, 22.2% of patients with diabetes were anemic, increasing to 52.4% in stage 4 CKD.
• According to NHANES survey, the prevalence of anemia increased with stage of CKD, from8.4% at stage 1to 53.4% at stage 5. A total of 22.8% of CKD patients with anemia reported being treated for anemiawithin the previous 3 months–14.6% of patients at CKD stages 1–2 and 26.4% of patients atstages 3–4.
• According to Sofue et al. (2020), approximately 13% of the Japanese adult population is estimated to haveCKD. The prevalence of anemia were 40.1% in patients with CKD stage G4 and 60.3% in patients with CKDstage G5.
• According to available literature, no gender bias was reported in case of Anemia in chronic kidney disease 

Country Wise- Anemia In Chronic Kidney Disease Epidemiology

The epidemiology segment also provides the Anemia In Chronic Kidney Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anemia In Chronic Kidney Disease Drug Chapters

The drug chapter segment of the Anemia In Chronic Kidney Disease report encloses the detailed analysis of Anemia In Chronic Kidney Disease marketed drugs and late-stage (Phase-III and Phase-II) Anemia In Chronic Kidney Disease pipeline drugs. It also helps to understand the Anemia In Chronic Kidney Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Anemia In Chronic Kidney Disease Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Anemia In Chronic Kidney Disease treatment.

Anemia In Chronic Kidney Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Anemia In Chronic Kidney Disease treatment.

GX-E4: Genexine

GX-E4 developed by Genexine, is a long-acting erythropoiesis-stimulating agent. Differing from marketed glycosylation or PEGylation products, it uses the hyFc fusion protein technology to maximize the half-life of the efficacy. It is intended for the treatment and for maintenance of anemia induced by chronic kidney disease with or without dialysis. Safety and tolerability were evaluated from the Phase I clinical trial in healthy volunteers, and the Phase II clinical trial in anemia patients with CKD has been completed, and the product is currently in Phase III trial with patients in 7 countries in Asia and Oceania. Its non-inferiority results compared to MIRCERA (methoxy polyethylene glycol-epoetin beta) were presented at the World Congress of Nephrology (WCN2023).

AND017: Kind Pharmaceuticals

AND017 by Kind Pharmaceuticals, a small molecular inhibitor of prolyl hydroxylase (PHI), mimics the natural physiological regulation under hypoxia condition to stabilize HIF and promote the production of red blood cells to treat anemia. This PHI can be orally administered without supplement of intravenous iron; thus, it is anticipated to improve patients' compliance. Most importantly, PHIs are expected to have a reduced risk of cardiovascular events, allowing PHIs to revolutionize the treatment of CKD-induced anemia. The structure of AND017 was discreetly designed to have high potency, superior desired tissue distribution, and excellent drug ability; AND017 has the best-in-class potential among the existing PHIs in treating CKD-induced anemia. The AND017 program is under Phase II clinical development. In January 2021, Kind Pharmaceuticals received the formal notification from the US FDA approving the IND of AND017 to treat anemia due to chronic kidney disease for Phase II clinical trials. In April 2023, the company started a Phase II, multicenter, open-label, randomized, active-controlled study of the efficacy and safety of AND017 in the treatment of anemia in patients with chronic kidney disease on dialysis.

DISC-0974: Disc Medicine

DISC-0974 is a first-in-class monoclonal antibody against hemojuvelin (HJV) to suppress the production of hepcidin and enhance iron levels to treat anemia of inflammation. DISC-0974 was in-licensed from AbbVie and is in advanced preclinical development. Disc Medicine has completed IND-enabling studies and initiated a Phase I clinical study in healthy volunteers in 2021. The company plans to develop DISC-0974 to treat multiple forms of anemias of inflammation. The company has initiated a Phase Ib multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DISC-0974 in participants with non-dialysis dependent chronic kidney disease and anemia.

Anemia In Chronic Kidney Disease Market Outlook

The Anemia In Chronic Kidney Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Anemia In Chronic Kidney Disease market trends by analyzing the impact of current Anemia In Chronic Kidney Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Anemia In Chronic Kidney Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Anemia In Chronic Kidney Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Anemia in Chronic Kidney Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Anemia in Chronic Kidney Disease market in 7MM.

The United States: Anemia In Chronic Kidney Disease Market Outlook

This section provides the total Anemia In Chronic Kidney Disease market size and market size by therapies in the United States.

EU-5 Countries: Anemia In Chronic Kidney Disease Market Outlook

The total Anemia In Chronic Kidney Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan: Anemia In Chronic Kidney Disease Market Outlook

The total Anemia in Chronic Kidney Disease market size and market size by therapies in Japan is also mentioned.

Anemia In Chronic Kidney Disease Drug Uptake

This section focuses on the rate of uptake of the potential Anemia In Chronic Kidney Disease drugs recently launched in the Anemia In Chronic Kidney Disease market or expected to get launched in the market during the study period 2020-2034. The analysis covers the Anemia In Chronic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.   

Anemia In Chronic Kidney Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Anemia In Chronic Kidney Disease market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Anemia In Chronic Kidney Disease Pipeline Development Activities

The Anemia In Chronic Kidney Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses key Anemia In Chronic Kidney Disease companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Anemia In Chronic Kidney Disease market report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Anemia In Chronic Kidney Disease emerging therapies.

Reimbursement Scenario in Anemia In Chronic Kidney Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Anemia In Chronic Kidney Disease market trends, we take KOLs and SMEs ' opinions working in the Anemia In Chronic Kidney Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies, treatment patterns or Anemia In Chronic Kidney Disease market trends. This will support the clients in a potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Anemia In Chronic Kidney Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends on the data availability.

Scope of the Anemia In Chronic Kidney Disease Market Report

• The report covers a descriptive overview of Anemia in Chronic Kidney Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Anemia In Chronic Kidney Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Anemia in Chronic Kidney Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Anemia In Chronic Kidney Disease market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anemia In Chronic Kidney Disease market

Anemia In Chronic Kidney Disease Market Report Highlights

• In the coming years, the Anemia in Chronic Kidney Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Anemia In Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Anemia In Chronic Kidney Disease. The launch of emerging therapies will significantly impact the Anemia in Chronic Kidney Disease market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anemia In Chronic Kidney Disease
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Anemia In Chronic Kidney Disease Market Report Insights

• Anemia In the Chronic Kidney Disease Patient Population
• Therapeutic Approaches
• Anemia In Chronic Kidney Disease Pipeline Analysis
• Anemia In Chronic Kidney Disease Market Size and Trends
• Anemia In Chronic Kidney Disease Market Opportunities
• Impact of Upcoming Anemia In Chronic Kidney Disease Therapies

Anemia In Chronic Kidney Disease Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Anemia In Chronic Kidney Disease Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Anemia In Chronic Kidney Disease Market
• Anemia In Chronic Kidney Disease Drugs Uptake

Anemia In Chronic Kidney Disease Market Report Assessment

• Current Treatment Practices
• Unmet Needs
• Anemia In Chronic Kidney Disease Pipeline Product Profiles
• Anemia In Chronic Kidney Disease Market Attractiveness
• Anemia In Chronic Kidney Disease Market Drivers and Barriers

Key Questions

Anemia In Chronic Kidney Disease Market Insights:

• What was the Anemia In Chronic Kidney Disease drug class share (%) distribution in 2020, and how would it look like in 2034?
• What would be the Anemia In Chronic Kidney Disease total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Anemia In Chronic Kidney Disease market size during the forecast period (2020-2034)?
• At what CAGR, the Anemia In Chronic Kidney Disease market is expected to grow by 7MM during the forecast period (2020-2034)?
• What would be the Anemia In Chronic Kidney Disease market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Anemia In Chronic Kidney Disease market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the Anemia In Chronic Kidney Disease market dynamics and subsequent analysis of the associated trends?

Anemia In Chronic Kidney Disease Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Anemia In Chronic Kidney Disease?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Anemia In Chronic Kidney Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Anemia In Chronic Kidney Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anemia In Chronic Kidney Disease?
• Out of all 7MM countries, which country would have the highest prevalent population of Anemia In Chronic Kidney Disease during the forecast period (2020-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Anemia In Chronic Kidney Disease treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Anemia In Chronic Kidney Disease in the USA, Europe, and Japan?
• What are the Anemia In Chronic Kidney Disease marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many Anemia In Chronic Kidney Disease companies are developing therapies for the treatment of Anemia In Chronic Kidney Disease?
• How many therapies are in-development by each company for Anemia In Chronic Kidney Disease treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Anemia In Chronic Kidney Disease treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Anemia In Chronic Kidney Disease therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anemia In Chronic Kidney Disease and their status?
• What are the current challenges faced in Anemia in Chronic Kidney Disease drugs development?
• What are the key designations that have been granted for the emerging therapies for Anemia in Chronic Kidney Disease?
• What are the global historical and forecasted Anemia In Chronic Kidney Disease market?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Anemia in Chronic Kidney Disease market
• To understand the future market competition in the Anemia in Chronic Kidney Disease market, and an Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Anemia In Chronic Kidney Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming Anemia in Chronic Kidney Disease companies in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Anemia In Chronic Kidney Disease market
• To understand the future market competition in the Anemia In Chronic Kidney Disease market